Join to View Full Profile
100 Cummings CenterSuite 241-DBeverly, MA 01915
Dr. Bolger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Graeme Bolger is an oncologist based in Beverly, MA, specializing in genitourinary and hematologic oncology. His medical education includes a residency in Internal Medicine at Johns Hopkins University and a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. From 2000 to 2015, he has served as an Associate Professor at the University of Alabama, following his tenure as an Assistant Professor at the University of Utah Health. Dr. Bolger has expertise in conditions such as hematologic oncology, renal cell carcinoma, and prostate cancer. His research has been published extensively, with significant contributions to understanding cAMP-signaling in cancers and PDE4 cyclic AMP phosphodiesterases. He has been recognized as one of America's Top Doctors and Top Doctors for Cancer by Castle Connolly.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
Johns Hopkins UniversityResidency, Internal Medicine, 1981 - 1984
McGill University Faculty of MedicineClass of 1981
Certifications & Licensure
AL State Medical License 2000 - 2024
UT State Medical License 1994 - 2002
WA State Medical License 1984 - 1995
MD State Medical License 1984 - 1994
NY State Medical License 1991 - 1994
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 5 citationsCyclic nucleotide phosphodiesterases as drug targets.Michy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, Claire Lugnier, Christian Hesslinger
Pharmacological Reviews. 2025-05-01 - 17 citationsThe cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.Graeme B Bolger
Frontiers in Endocrinology. 2022-01-01 - 22 citationsThe PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related Multigene Family.Graeme B. Bolger
Trends in Genetics. 2021-04-05
Journal Articles
- The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform.Yarwood, S.J., Steele, M.R., Scotland, G., Houslay, M.D., Bolger, G.B., J. Biol. Chem, 1999
- Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D geneBolger, Biochem J, 1997
- Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3Huston, E, Biochem J, 1997
Press Mentions
New Clinical Decision Support Tool for Molecular and Genetic Testing LaunchedSeptember 2nd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
